NOVO NORDISK : GLP-1 Rx Tracker; down week for Wegovy -pill, inflection signs for sc?

Research evidence excerpt

NOVO NORDISK : GLP-1 Rx Tracker; down week for Wegovy -pill, inflection signs for sc?

Paribas Securities Corp is a FINRA member firm and broker-dealer registered with

U.S. Securities Exchange Commission. With respect to any United States persons who are institutional investors BNP Paribas Securities Corp. is the

distributor of this research report. This report is not intended for retail investors. Any United States person wishing to obtain further information or to

effect a transaction in any security discussed in this report should do so only through BNP Paribas Securities Corp., which has distributed this report

in the United States and, subject to the above, accepts responsibility for its contents. With respect to clients domiciled in Canada, BNP Paribas

Securities Corp. is the distributor of this research report operating under the “general adviser exemption” or the “international dealer exemption”. BNP

Paribas Securities Corp. does not distribute this research report in any other jurisdictions.

Other Jurisdictions: The distribution of this report in other jurisdictions or to residents of other jurisdictions may also be restricted by law, and persons into

whose possession this report comes should inform themselves about, and observe, any such restrictions. By accepting this report you agree to be bound

by the foregoing instructions. This report is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident of or

located in any locality, state, country, or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation.

BNP Paribas Research Novo Nordisk / Novo Nordisk ADR 15 MAY 2026 page 11

lcecil1@tulane.edu Loren Cecil 05/22/26 01:01:44 AM Tulane University